Article info
Review
Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis
- Correspondence to Dr Anthony Allen Reeves, Department of Clinical and Administrative Sciences, Larkin University College of Pharmacy, Miami, FL 33169, USA; a.allenreeves13{at}gmail.com
Citation
Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis
Publication history
- Received October 3, 2020
- Revised January 4, 2021
- Accepted January 7, 2021
- First published March 29, 2021.
Online issue publication
May 17, 2021
Article Versions
- Previous version (29 March 2021).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.